How is the Ph-like signature being incorporated into ALL therapy?. Issue 3 (September 2017)

• Record Type: Journal Article
• Authors: Maese, Luke; Tasian, Sarah K.; Raetz, Elizabeth A.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 30:Issue 3(2017)
• Page Start: 222
• Page End: 228
• Publication Date: 2017-09
• Subjects: Acute lymphoblastic leukemia -- Philadelphia chromosome-like -- tyrosine kinase inhibitor -- Janus kinase inhibitor -- Imatinib -- Dasatinib -- Ruxolitinib; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2017.06.001
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a recently identified high risk disease subtype characterized by a gene expression profile similar to that observed in Philadelphia chromosome-positive (Ph-positive) ALL, but without an underlying BCR-ABL1 translocation. Adults and children with Ph-like ALL harbor a diversity of alterations that all lead to activated kinase signaling. Outcomes for patients with Ph-like ALL are poor, which has prompted investigation into the role of tyrosine kinase inhibitor (TKI)-based therapies for this disease. Several clinical trials are now ongoing that include screening for the Ph-like signature and treatment of patients with Ph-like ALL with TKI therapy. This review examines how testing for Ph-like ALL is being incorporated into clinical trials.